当前位置: X-MOL 学术Ther. Adv. Med. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)
Therapeutic Advances in Medical Oncology ( IF 4.9 ) Pub Date : 2020-03-06 , DOI: 10.1177/1758835920910913
Hao Xie 1 , Jacqueline M Lafky 2 , Bruce W Morlan 3 , Philip J Stella 4 , Shaker R Dakhil 5 , Gerald G Gross 6 , William S Loui 7 , Joleen M Hubbard 1 , Steven R Alberts 1 , Axel Grothey 8
Affiliation  

Colorectal cancer (CRC) is one of the most common and deadliest malignancies in the United States, where it has been estimated that about 145,600 people were diagnosed with CRC and 51,020 patients died from this disease in 2019.1 Over the past decade, medical treatment options for metastatic colorectal cancer (mCRC) have greatly expanded with the introduction of novel chemotherapeutic agents (e.g. oxaliplatin and irinotecan), biologic inhibitors of the vascular endothelial growth factor (VEGF) system [e.g. bevacizumab (BEV)], and epidermal growth factor receptors in RAS wild-type cancers (panitumumab and cetuximab). Despite these improvements, the 5-year survival for mCRC patients is still only 11%.2 There is a great unmet need to develop novel therapeutic approaches that further improve outcome in mCRC, in particular in patients who have shown tumor progression after exhausting all standard treatment options.

中文翻译:

索拉非尼和贝伐单抗双重 VEGF 抑制作为转移性结直肠癌的补救治疗:II 期北中心癌症治疗组研究 N054C (Alliance) 的结果

结直肠癌 (CRC) 是美国最常见和最致命的恶性肿瘤之一,据估计,2019 年约有 145,600 人被诊断出患有 CRC,51,020 名患者死于这种疾病。1在过去十年中,医疗随着新型化疗药物(如奥沙利铂和伊立替康)、血管内皮生长因子 (VEGF) 系统的生物抑制剂 [如贝伐单抗 (BEV)] 和表皮生长因子受体的引入,转移性结直肠癌 (mCRC) 的选择已大大扩展在RAS野生型癌症(帕尼单抗和西妥昔单抗)中。尽管有这些改进,mCRC 患者的 5 年生存率仍然只有 11%。2开发新的治疗方法以进一步改善 mCRC 的结果,特别是在用尽所有标准治疗方案后表现出肿瘤进展的患者,存在巨大的未满足需求。
更新日期:2020-04-21
down
wechat
bug